Track topics on Twitter Track topics that are important to you
TSRL, Inc., a privately-held preclinical accelerator based in Ann Arbor, Michigan, announced today that the company was awarded up to $3.6 million in grant funding from the National Institute of Allergy & Infectious Diseases to develop novel antibacterials for difficult-to-treat skin and soft tissue infections.
Ann Arbor, Michigan (PRWEB) September 11, 2017
TSRL Inc., a privately-held preclinical "accelerator" that works with academic and industry partners to develop early-stage anti-infective therapeutics and drug delivery technologies, announced today the the company was awarded a Phase I Small Business Technology Transfer (STTR) grant and a Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). TSRL and its collaborators from Purdue University and the University of Washington were awarded up to $3.6 million over the next three years to develop a portfolio of novel antibacterials for difficult-to-treat infections.
Under the Phase I STTR grant, the Purdue-TSRL team will receive up to $600,000 over the next two years to expedite the preclinical development of a new class of cell-penetrating antimicrobial peptides (CPAPs). Organic chemist and Professor Dr. Jean Chmielewski and her team at Purdue University's Department of Chemistry engineered unnatural amino acids into peptides that target intracellular bacterial pathogens, breakdown established biofilms, and reduce inflammatory cytokines prevalent in complicated skin and soft tissue infections.
The CPAPs have activity against both Gram-positive and Gram-negative bacteria and can be used to deliver other agents to the site of infection. This grant, awarded in collaboration with microbiologist Dr. Mohamed Seleem of the Purdue's School of Veterinary Medicine, will explore the efficacy of new chemistries and formulations of the CPAPs.
"Bacterial infection is a serious complication in the management of chronic non-healing wounds, and we are incredibly excited to continue our highly successful collaboration with TSRL and Dr. Seleem to apply our peptide-based chemistry to this significant medical problem” said Prof. Chmielewski.
Under the Direct-to-Phase II SBIR, TSRL and collaborators at the University of Washington will receive up to $3,000,000 over the next three years to develop and test novel chemistries around methionyl-tRNA synthase inhibitors (MetRS). A major goal of the MetRS program is to develop orally-available, best-in-class agents for the treatment of systemic multi-drug resistant infections caused by Gram-positive bacteria. Drugs with new mechanisms of action are urgently needed since the emergence of methicillin-resistant staphylococcus aureus (MRSA).
A major health issue in developed countries, CDC statistics show that in 2011 there were 80,461 severe infections and 11,285 deaths due to MRSA in the United States alone. This grant was awarded in collaboration with Dr. Fred Buckner, a physician-scientist at the Department of Allergy and Infectious Diseases, and Dr. Erkang Fan, a medicinal chemist, both at the University of Washington School of Medicine.
“Dr. Fan and I are very pleased to receive this NIH funding in partnership with TSRL to develop new antibiotics for MRSA and other infections caused by Gram positive bacteria," said Dr. Buckner. "The combined expertise of the scientists at University of Washington and at TSRL will make an outstanding team to bring forward much needed therapeutics to combat the spreading problem of multi-drug resistant infectious diseases.”
About TSRL, Inc.:
TSRL, Inc. is a privately-held preclinical accelerator based in Ann Arbor, Michigan. We collaborate with partners in academia and industry to develop early-stage anti-infective therapeutics and drug delivery technologies. In these collaborations, we provide infrastructure, drug development expertise, and access to non-dilutive funding. Our asset-centric portfolio is built on promising lead-stage anti-infective compounds. More information about TSRL, Inc. is available on the company website http://www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 7346634233 x236, elipka(at)tsrlinc(dot)com.
Acknowledgment of NIH Support:
This research is supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health under Award Numbers R41AI132102 and R44AI134190. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
For the original version on PRWeb visit: http://www.prweb.com/releases/2017/08/prweb14605084.htmNEXT ARTICLE
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...